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species. However, the new spirochete
is distinct from all other known
Borrelia  spp. with an available 16S
rDNA sequence in the GenBank data-
base. Its partial 16S rDNA sequence
differed by 3.3% to 4.2% from 9 LB
group species and 2.4% to 3.4% from
15 relapsing fever group species. For
comparison, intragroup sequence dif-
ferences were <1.9%. On this basis, as
well as the finding of partial IGS
sequences (GenBank accession nos.
AY668955 and AY668956) that were
unique among all Borrelia spp. stud-
ied to date (3,5), we propose that this
is a new species of Borrelia, provi-
sionally named Borrelia davisii in
honor of Gordon E. Davis for his con-
tributions to Borrelia  research and
taxonomy.
While the new species was detect-
ed in 8 of 131 P. leucopus blood sam-
ples by using PCR for the IGS, the
assays for this organism in the DNA
extracts of 282 I. scapularis nymphs
(4) from the same geographic site
were uniformly negative (p = 0.0003,
2-sided Fisher exact test). This find-
ing suggests that the new spirochete
has another vector. The only other
documented tick species that has been
found feeding in small numbers on P.
leucopus  in Connecticut is
Dermacentor variabilis (7). Holden et
al. reported the presence of Borrelia
in D. variabilis ticks in California by
using PCR with genus-specific
primers, but the species in these ticks
was not identified by sequencing (8). 
Although how B. miyamotoi and
B. davisii affect the health of humans
and other animals remain to be deter-
mined, our finding of 3 Borrelia
species with overlapping life cycles in
the same host in the same area shows
that the ecology of Borrelia is more
complex than was imagined. The
presence of species other than B.
burgdorferi in a major reservoir will
have to be considered in future sur-
veys and interventions. 
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To the Editor: The global
Military Health System maintains
electronic inpatient (Standard
Inpatient Data Record, SIDR) and
outpatient (Standard Ambulatory
Data Record, SADR) clinical diag-
nostic coded data generated by the
Department of Defense Composite
Health Care System (CHCS), an elec-
tronic system that tracks and stores
administrative and other patient
encounter data. Because these
records are readily available, wide-
spread monitoring of these data as a
means of medical surveillance has
been suggested (1,2). Only 1 study in
the literature assessed electronic cod-
ing reliability of these data (3); those
authors found SIDRs to be a reliable
source of billing data for common
diagnoses, not including notifiable
infectious diseases. We compared
SADR and SIDR infectious disease
diagnostic codes to laboratory data to
assess the usefulness of these datasets
in notifiable disease surveillance.
We identified SADRs and SIDRs
coded for malaria, syphilis, acute hep-
atitis B, and Lyme disease in sailors,
marines, and their family members,
who were beneficiaries for medical
care in a large metropolitan area.
Medical encounters from January 1,
2001, to June 30, 2002, were studied.
All records for the same patient with
the same diagnostic code(s) were con-
sidered as 1 encounter. Records wereLETTERS
selected on the basis of International
Classification of Diseases, Ninth
Revision, Clinical Modification
(ICD-9-CM) codes (4) as defined by
the Department of Defense (5).
Laboratory data were not part of
SIDRs and SADRs but were part of
CHCS. 
For records with diagnostic codes
relating to any of the 4 diseases of
interest, laboratory records were
searched to determine: 1) whether the
provider ordered an appropriate test
or tests and 2) if these were ordered,
were the test results confirmatory
(positive). Appropriate and confirma-
tory test results were determined by
using published references (5–7) and
local laboratory practices. For malar-
ia, a blood smear was considered an
appropriate test with a positive blood
smear accepted as confirmatory (5,6).
We considered both nontreponemal
and treponemal tests to be appropri-
ate for syphilis but only a positive tre-
ponemal test as confirmatory (5,6).
For acute hepatitis B, we considered
hepatitis B surface antigen or
immunoglobulin (Ig) M anti-hepatitis
B core (anti-HBc) to be an appropri-
ate test, but only a positive IgM anti-
HBc was accepted as confirmatory
(5,6). We considered enzyme
immunoassay total antibody screens
or Western blot (WB) IgG or IgM
tests to be appropriate for Lyme dis-
ease and accepted any positive test as
confirmatory (5–7). χ2 calculations
were conducted (α = 0.05). 
Twenty-one SIDRs and 155
SADRs met the selection criteria
(Table). While 61.9% of SIDRs stud-
ied had appropriate laboratory tests
ordered, only 19.0% had associated
confirmatory results in CHCS. For
outpatient records, 64.5% had appro-
priate tests ordered, and 15.5% had
confirmatory results. Among the
SADRs, the proportions of appropri-
ate laboratory tests for the diseases
studied differed significantly (sum-
mary  χ2 =11.5, p = 0.01). These
results suggest that tracking electron-
ic SADR and SIDR datasets for the
selected reportable diseases could
produce a high number of false-posi-
tive reports; in this study, 81.0% of
inpatient and 84.5% of outpatient
reports would lack a confirmatory
laboratory test result. 
This initial evaluation is limited
but supports the need to evaluate elec-
tronic datasets before using them for
medical surveillance. We examined
only ICD-9-CM coded records of
selected diseases from 1 geographic
area, with resulting small samples.
Therefore, our results may not be gen-
eralizable. This study was restricted to
laboratory, inpatient, and outpatient
data recorded within 1 coordinated
military system. Laboratory testing or
clinical visits may have occurred out-
side of this network and may not have
been captured in this study.
Laboratory data were not recorded or
stored in a standardized format in
CHCS, increasing the likelihood of
misclassification. We did not evaluate
all related sources of data, including
the hard-copy clinical records, so we
do not know the completeness of the
ICD-9-CM codes or the extent of
ICD-9-CM code misclassification.
Additionally, local clinical practices
in terms of both ordering laboratory
tests and coding diagnoses for the dis-
eases studied were not defined. 
Future studies would benefit from
comparing reported medical events,
paper medical records, and electronic
datasets to include determination of
sensitivity as well as positive predic-
tive value (2,8,9). Discordance in
these data sources should be investi-
gated for miscoding, incomplete data,
and unexpected clinical practices. 
Efforts to improve medical record
coding at military medical treatment
facilities are under way (10).
Additionally, standardization of
CHCS laboratory test files, including
adoption of the Logical Observation
Identifiers Names and Codes system
for standardized reporting of test
names, is under way (available from
http://www.ha.osd.mil/policies/
2003/03-023.pdf). However, a docu-
mented, complete, reliable, and close-
ly monitored single source of data for
medical surveillance and disease
reporting does not currently exist.
Therefore, surveillance programs for
infectious diseases in the US military
should include monitoring of multi-
ple, related sources of data and infor-
mation (e.g., electronic inpatient and
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outpatient encounters, laboratory
results, and pharmacy data). All of
these sources should be evaluated for
completeness and accuracy.
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To the Editor: A 37-year-old
woman, a logistics director for a non-
government organization, returned to
France in March 2004 from an 18-day
trip to Guinea, Senegal, and Sierra
Leone. Fever, chills, and myalgia
developed in the woman 3 days before
she returned to France, and she treat-
ed herself with aspirin and paraceta-
mol (acetaminophen). Malaria pro-
phylaxis was taken neither during nor
after the trip. 
The day after returning to France,
the woman’s condition progressively
worsened; diarrhea and extreme
weakness that led to the inability to
walk developed. Ten days after her
return, she was admitted to the local
hospital and treated with intravenous
quinine and oral doxycycline (2 g per
day) after thick and thin blood films
showed 3% parasitemia with
Plasmodium falciparum. Three days
later, she was still febrile and had con-
junctival jaundice, vomiting, insom-
nia, and moderate hemorrhagic mani-
festations (epistaxis, blood in urine
and feces). Three days after initial
hospitalization, the patient was trans-
ferred to the Infectious Diseases Unit
in Marseille; fever (39.5°C) contin-
ued, and hepatosplenomegaly devel-
oped. Biologic analyses showed dis-
seminated intravascular coagulation
with platelet count of 22,000/µL, an
elevated prothrombin time (54%
higher than the control value), a
longer activated clotting time (51 sec-
onds versus a control value of 34 sec-
onds), a fibrinogen level of 0.9 g/dL,
exaggerated plasma fibrin formation
and degradation, and hepatic cytolysis
with both aspartate aminotransferase
and alanine aminotransferase levels of
80 U/L. 
Although acute malaria had been
diagnosed, viral serologic tests were
performed because the patient had
returned from a tropical country with
a fever. Persons in these circum-
stances are systematically adminis-
tered a series of tests to determine the
cause of their fever. Serologic tests for
dengue performed on the acute-phase
serum (collected 13 days after onset
of symptoms) and convalescent-phase
serum (collected 23 days after onset
of symptoms) showed the presence of
immunoglobulin (Ig) M (titers 1:800
and 1:3,200, respectively) and IgG
(titers 1:400 and 1:3,200, respective-
ly), which suggested that the patient
had dengue fever and malaria concur-
rently. These results were obtained by
using the Dengue Duo IgM-capture
and IgG-indirect enzyme-linked
immunosorbent assay (Biotrin,
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 7, July 2005 1153
1Preliminary findings were presented at
the US Army Force Health Protection
Conference, August 2003, Albuquerque
NM, the International Conference on
Emerging Infectious Diseases, February
2004, Atlanta, GA, and the Navy
Occupational Health and Preventive
Medicine Workshop, March 2004, Norfolk,
VA.